Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Starting treatment news

Show

From To
Uganda: Aids Patients Reject Bitter ARVs

The Uganda Coalition for Access to Essential Medicine (UCAEM) has asked government to withdraw and cease use of non-film coated tenofovir and lamivudine, dubbing the drug combination as notoriously bitter. "People living with HIV will more likely stop taking treatment than use this medicine," said Margaret Happy, the advocacy officer of the International Community of Women in East Africa (ICWEA).

Published
10 September 2014
From
Allafrica.com
South African women living with HIV subtype C experience rapid CD4 cell loss

A third of women living with HIV subtype C have a fall in their CD4 count to below 350 cells/mm3 within a year of seroconversion, investigators

Published
05 August 2014
By
Michael Carter
Efavirenz use not linked to neurocognitive impairment

People who use antiretroviral regimens containing efavirenz (Sustiva or Stocrin, also in the Atripla coformulation) were not at higher risk for impaired neurocognitive function, either overall or when looking

Published
25 July 2014
By
Liz Highleyman
Men Who Have Sex With Men Getting Treatment Sooner

Long-term trends indicate that European men who have sex with men are seeking treatment for HIV at earlier stages of their disease, researchers reported here.

Published
25 July 2014
From
MedPage Today
Dolutegravir demonstrates good efficacy despite resistance

Antiretroviral regimens containing the recently approved HIV integrase inhibitor dolutegravir (Tivicay) demonstrated high rates of viral suppression even in treatment-experienced people who had virus with resistance to

Published
24 July 2014
By
Liz Highleyman
Could HIV treatment mean safer sex?

A meta-analysis of every study that has looked at the sexual behaviour of people after starting HIV treatment has found not a single instance of so-called

Published
24 July 2014
By
Gus Cairns
Maraviroc fails to match tenofovir/emtricitabine for first-line HIV treatment

An NRTI-sparing dual antiretroviral regimen containing maraviroc (Celsentri) plus ritonavir-boosted darunavir (Prezista) was found to be less effective than a standard combination with tenofovir/emtricitabine (the drugs in Truvada), according

Published
23 July 2014
By
Liz Highleyman
Therapy with newer, safer antiretrovirals an option for the majority of HIV-positive patients

The majority of people taking antiretroviral therapy (ART) that includes drugs associated with long-term side-effects may have the option of switching to a novel regimen

Published
11 July 2014
By
Michael Carter
Option B+: In obstacle courses to lifelong antiretroviral treatment, hurdles are higher for pregnant women, study says

Work conflicts, hidden HIV status, and bad treatment by staff are among the hurdles keeping women living with HIV from continuing antiretroviral treatment for life following childbirth, according to a article published last month ahead of print in the Journal of Acquired Immune Deficiency Syndromes.

Published
09 July 2014
From
Science Speaks
New ARV prescribing guidelines for London (2014)

The guidelines are the result of a therapeutic tender, which encourages drug manufacturers to offer volume discounts for different stages of the treatment pathway, for example, for preferred use in first-line, second-line and multiple resistant treatment.

Published
01 July 2014
From
HIV i-Base
← First12345...63Next →

Filter by country